Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Should You Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $23.50, but opened at $22.69. Chugai Pharmaceutical shares last traded at $23.0950, with a volume of 19,079 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CHGCY shares. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Smbc Nikko Sec. raised Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Chugai Pharmaceutical has an average rating of “Buy”.

Chugai Pharmaceutical Stock Up 2.2%

The business has a 50-day moving average price of $25.81 and a 200-day moving average price of $27.23. The company has a market capitalization of $76.62 billion, a price-to-earnings ratio of 25.87 and a beta of 0.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Friday, April 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%. As a group, sell-side analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.